Nippon Kayaku
As of the edition of 20 October 2026, Nippon Kayaku runs 17 drugs, 14 of them marketed; it is on route A at 0 targets and on route B at 12 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paclitaxel | none listed | 0 |
| Cisplatin | none listed | 0 |
| Bevacizumab | Ends 2027 (orphan exclusivity) | 2 |
| Doxorubicin | none listed | 3 |
| Etoposide | none listed | 5 |
| Pemetrexed | none listed | 7 |
| Vincristine | none listed | 0 |
| Temozolomide | none listed | 0 |
| Topotecan | none listed | 1 |
| Infliximab | Ended 2018 (orphan exclusivity) | 3 |
| Vinblastine | none listed | 0 |
| Acyclovir | none listed | 0 |
| Cetrorelix | none listed | 1 |
| Taletrectinib | Ends 2033 (patent) | 8 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 12 targets.
All 12 rows on route A or B
In the product12 company-target rows on route A or B; 9 are not shown here, and no score is.
See all 12 targets where Nippon Kayaku needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 6 trials led
- Skin and connective tissue: 4 trials led
- Immune system: 2 trials led